ECORIN
Heparin is widely used to prevent and treat blood clots, which can lead to life-threatening conditions such as deep vein thrombosis, pulmonary embolism, and heart attacks. Because of its ability to prevent clot formation, heparin is indispensable in a variety of medical settings, including surgeries, dialysis, and the treatment of various cardiovascular disorders.
The safety and quality control risks associated with heparin stem primarily from its traditional production process, which involves extracting the anticoagulant from pig intestines. This method carries a significant risk of contamination, as impurities from the animal tissues can enter the final product. Past incidents have shown that contaminated heparin can lead to severe health complications, including fatalities.
While traditional heparin production relies on animal tissues, modern biosynthetic approaches aim to provide safer, more ethical alternatives. By leveraging advanced biotechnology, we are exploring innovative methods to produce heparin without the contamination risks and ethical concerns tied to conventional processes.
E. coli Nissle, a probiotic strain, is engineered to produce heparosan, a precursor to heparin.
Once heparosan is produced, it undergoes an enzymatic conversion process to become bioactive heparin.
Biosynthetic heparin offers key advantages over traditional methods, including a reduced risk of contamination by eliminating reliance on animal tissues, ensuring a purer and safer product. It also aligns with ethical practices, addressing animal welfare concerns while supporting cruelty-free production.
The development of biosynthetic heparin marks a pivotal step forward in ensuring safe, ethical, and reliable anticoagulant treatments. By embracing innovative technologies and addressing the challenges of traditional methods, we are building a future where medical treatments are not only effective but also responsible. Together, we can revolutionize healthcare and improve the lives of patients around the world.
© 2024 - Content on this site is licensed under a Creative Commons Attribution 4.0 International License. This repository used to create this website is available at gitlab.igem.org/2024/boston-boslab